lawsuits against tirzepatide Novo Nordisk, maker of the popular medications Ozempic and Wegovy, filed a lawsuit Tuesday the pharmaceutical company Eli Lilly, accusing it of making deceptive advertising claims about its weight-loss drug Zepbound Novo sues Lilly, claiming misleading

We'll have to see how effective they are, but the initial results are very promising, also the side effect profile

The metabolic pathway analysis (Fig

Racial and ethnic proportions were 39% Hispanic, 33% black, 27% white, and 2% American Indian or Alaskan Native

Biong M, Gram IT, Brill I, Johansen F, Solvang HK, Alnaes GIG, et al

What Changed in the Last 24 Hours On April 22, 2026 , the FDA Law Blog published Post 2 of 2 in its peptide compounding series

Unlike semaglutide, which acts on only the GLP-1 receptor, tirzepatide is a dual agonist that also activates the GIP (glucose-dependent insulinotropic polypeptide) receptor